Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen unamortized Debt Discount and Issuance Costs ($M) ($M)
Form 10-Q / 10-K Financing Arrangements Note (XBRL)
Latest, Q2 2026
1,317
Period ended Jun 30, 2026
Change on a year earlier
-1.1%
1,331 in Q2 2025
History
37 quarters
Since Q4 2015
Sources
31
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Unamortized Debt Discount and Issuance Costs ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,317 | -1.1% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,329 | -1.2% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,306 | -4.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,317 | -4.1% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,331 | -4.2% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,345 | -4.2% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,360 | -4.2% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,373 | -3.5% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,389 | -3.4% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,404 | -2.1% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,420 | +14.0% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,423 | +13.7% | Form 10-Q (filed 2023-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,438 | +15.5% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,434 | +14.4% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,246 | +2.7% | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,252 | +2.5% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,245 | +6.0% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,253 | +6.0% | Form 10-Q (filed 2022-04-28) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,213 | +2.1% | Form 10-K (filed 2023-02-09) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,221 | +2.1% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,174 | +38.3% | Form 10-Q (filed 2021-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,182 | +32.5% | Form 10-Q (filed 2021-04-28) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,188 | +36.9% | Form 10-K (filed 2022-02-16) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,196 | +36.8% | Form 10-Q (filed 2020-10-29) ↗ |
| Q2 2020 | Jun 30, 2020 | 849 | -3.7% | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2020 | Mar 31, 2020 | 892 | +0.7% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 868 | -3.1% | Form 10-Q (filed 2020-05-01) ↗ |
| Q3 2019 | Sep 30, 2019 | 874 | – | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 882 | – | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 886 | -3.7% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 896 | -3.6% | Form 10-Q (filed 2019-10-30) ↗ |
| Q1 2018 | Mar 31, 2018 | 920 | – | Form 10-Q (filed 2018-04-25) ↗ |
| Q4 2017 | Dec 31, 2017 | 929 | -199.3% | Form 10-Q (filed 2018-04-25) ↗ |
| Q4 2016 | Dec 31, 2016 | -936 | +345.7% | Form 10-K (filed 2017-02-14) ↗ |
| Q3 2016 | Sep 30, 2016 | 942 | – | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 1,011 | – | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | -210 | – | Form 10-K (filed 2017-02-14) ↗ |
Cite this data
StockData. (2026). Amgen Unamortized Debt Discount and Issuance Costs ($M) ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/debt_unamort_disc
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.